Telix Pharmaceuticals (TLPPF) Other Accumulated Expenses (2024 - 2025)
Telix Pharmaceuticals' (TLPPF) quarterly Other Accumulated Expenses came in at $72.4 million in Q4 2025, down 16.0% year-over-year from $86.3 million in Q4 2024, and down 16.0% quarter-over-quarter from $86.3 million in Q4 2024.
Powered by 
Analysis
Telix Pharmaceuticals (TLPPF) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLPPF) has reported Other Accumulated Expenses for 2 consecutive years, with $72.4 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Other Accumulated Expenses fell 16.0% year-over-year to $72.4 million in Q4 2025; TTM through Dec 2025 was $72.4 million, a 16.0% decrease from a year earlier, with the FY2025 full-year figure at $72.4 million, down 16.0% from the prior year.
- Other Accumulated Expenses was $72.4 million for Q4 2025 at Telix Pharmaceuticals, down from $86.3 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $86.3 million in Q4 2024 and troughed at $72.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.49 Bn | 198.50 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.93 Bn | 177.75 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.39 Bn | 124.53 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.17 Bn | 74.18 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.05 Bn | 55.87 Bn | 1.37 Bn |
| 6 | Moderna | 55.19 Bn | 50.05 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.99 Bn | 30.68 Bn | 992.69 Mn |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn |
| 10 | Telix Pharmaceuticals | 3.72 Bn | 3.43 Bn | - |